Epigenetic modulators from “The Big Blue”: A treasure to fight against cancer
- Authors
- Type
- Published Article
- Journal
- Cancer Letters
- Publisher
- Elsevier
- Publication Date
- Sep 23, 2014
- Volume
- 351
- Issue
- 2
- Pages
- 197–197
- Identifiers
- DOI: 10.1016/j.canlet.2014.06.005
- Source
- LBMCC
- Keywords
- License
- Green
Abstract
Cancer remains a major public health problem in our society. The development of potent novel anti-cancer drugs selective for tumor cells is therefore still required. Deregulation of the epigenetic machinery including DNA methylation, histone modifications and non-coding RNAs is a hallmark of cancer, which provides potential new therapeutic targets. Natural products or their derivatives represent a major class of anti-cancer drugs in the arsenal available to the clinician. However, regarding epigenetically active anti-cancer agents for clinics, the oceans represent a largely untapped resource. This review focuses on marine natural compounds with epigenetic activities and their synthetic derivatives displaying anti-cancer properties including largazole, psammaplins, trichostatins and azumamides.